Thermo Fisher's price for CorEvitas, a real-world-evidence registry company, spread over the patients its registries follow (whole-company acquisition, arithmetic over two stated numbers)
$912.5 million
USD per patient followed in CorEvitas's registries
“Under deal terms announced Thursday, Thermo Fisher will pay $912.5 million cash to acquire privately held CorEvitas. ... The company says its technology platform gathers structured patient clinical data from about 400 investigator sites and more than 100,000 patients followed.”
- Kind of source
- Named press report
- Read on
- 2026-11-07
- Daily check
- Quote found at the source on 2026-11-07
- What to know
- Whole-company sale of a registry business (12 registries, mostly autoimmune and inflammatory disease) with its staff, pharma contracts and investigator network, not a data price. Each registry record mixes physician-reported measures with patient-reported outcomes: PPD's registry pages say the registries capture 'clinician- and patient-reported data' (PROMIS and WPAI questionnaires in the IBD registry, for example). Thermo Fisher's 10-Q for Q3 2023 records the deal closing on 14 August 2023.
- Arithmetic
- $912,500,000 / 100,000 patients = $9,125 per patient followed (an upper figure, since the count is 'more than 100,000').
Used in
Kept as evidence; no figure on the platform is computed from it yet.